Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the
effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with
Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28
days), and a 6-week Treatment Period (during which participants will receive either NMRA
335140 or placebo). At the completion of the 6-week Treatment Period, participants who
complete the study, provide informed consent, and meet the eligibility criteria may enter an
extension study (NMRA 335140 501).